Fig. 2From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)Total pain burden sensitivity analysis: total monthly severity-weighted duration in hours adjusted for change in migraine headache days for patients with episodic migraine and chronic migraine. Greater decreases in total pain burden (severity-weighted hours) were observed with galcanezumab treatment Months 1 to 6 overall for patients with episodic migraine and Months 1 to 3 overall for patients with chronic migraineBack to article page